Cite
HARVARD Citation
Mazza, S. et al. (n.d.). AF.50 SAFETY AND CLINICAL EFFICACY OF THE DOUBLE SWITCH FROM ORIGINATOR INFLIXIMAB TO BIOSIMILARS CT-P13 AND SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (SCESICS): A MULTICENTER COHORT STUDY. Digestive and liver disease. pp. S159-. [Online].